(Q34948216)

1 July 2019

review article

1 reference

title

Cannabidiol: a promising drug for neurodegenerative disorders? (English)

1 reference

1 July 2019

0 references

1 reference

Caterina Scuderi

4

0 references

Giuseppe Esposito

object named as

Giuseppe Esposito

2

0 references

Luca Steardo

object named as

Luca Steardo

5

0 references

author name string

Teresa Iuvone

1

1 reference

1 July 2019

Daniele De Filippis

3

1 reference

1 July 2019

publication date

1 January 2009

1 reference

1 July 2019

CNS Neuroscience & Therapeutics

published in

1 reference

1 July 2019

volume

15

1 reference

1 July 2019

issue

1

1 reference

1 July 2019

page(s)

65-75

1 reference

1 July 2019

Neuroprotective effect of (-)Delta9-tetrahydrocannabinol and cannabidiol in N-methyl-D-aspartate-induced retinal neurotoxicity: involvement of peroxynitrite

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2008.00065.X

Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2008.00065.X

Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2008.00065.X

Neuroprotective antioxidants from marijuana.

21 January 2018

1 reference

12 December 2020

Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide

1 reference

12 December 2020

1 reference

12 December 2020

The endocannabinoid system protects rat glioma cells against HIV-1 Tat protein-induced cytotoxicity. Mechanism and regulation

1 reference

12 December 2020

Cannabidiol: an overview of some chemical and pharmacological aspects. Part I: chemical aspects

1 reference

12 December 2020

Nonpsychotropic cannabinoid receptors regulate microglial cell migration.

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of cannabinoids

1 reference

12 December 2020

Possible endocannabinoid control of colorectal cancer growth

1 reference

12 December 2020

Cannabis-based medicines--GW pharmaceuticals: high CBD, high THC, medicinal cannabis--GW pharmaceuticals, THC:CBD

1 reference

12 December 2020

Oral anti-inflammatory activity of cannabidiol, a non-psychoactive constituent of cannabis, in acute carrageenan-induced inflammation in the rat paw.

1 reference

12 December 2020

Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells

1 reference

12 December 2020

Win 55212-2, a cannabinoid receptor agonist, attenuates leukocyte/endothelial interactions in an experimental autoimmune encephalomyelitis model

1 reference

12 December 2020

Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation

1 reference

12 December 2020

An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis

1 reference

12 December 2020

Cannabidiol prevents infarction via the non-CB1 cannabinoid receptor mechanism

1 reference

12 December 2020

The nonpsychoactive component of marijuana cannabidiol modulates chemotaxis and IL-10 and IL-12 production of murine macrophages both in vivo and in vitro

1 reference

12 December 2020

Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism.

1 reference

12 December 2020

Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation.

1 reference

12 December 2020

Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease

1 reference

12 December 2020

Cannabidiol prevents cerebral infarction via a serotonergic 5-hydroxytryptamine1A receptor-dependent mechanism

1 reference

12 December 2020

The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy.

1 reference

12 December 2020

Cannabinol delays symptom onset in SOD1 (G93A) transgenic mice without affecting survival.

1 reference

12 December 2020

A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol

1 reference

12 December 2020

Identification and functional characterization of brainstem cannabinoid CB2 receptors

1 reference

12 December 2020

Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis

1 reference

12 December 2020

Agonistic properties of cannabidiol at 5-HT1a receptors

1 reference

12 December 2020

Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up.

1 reference

12 December 2020

Sativex for the management of multiple sclerosis symptoms

1 reference

12 December 2020

The marijuana component cannabidiol inhibits beta-amyloid-induced tau protein hyperphosphorylation through Wnt/beta-catenin pathway rescue in PC12 cells

1 reference

12 December 2020

Cannabinoid pharmacology: the first 66 years

1 reference

12 December 2020

Natural history of multiple sclerosis: a unifying concept

1 reference

12 December 2020

Cannabinoid CB2 receptors: Immunohistochemical localization in rat brain

1 reference

12 December 2020

Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors

1 reference

12 December 2020

Cannabidiol inhibits inducible nitric oxide synthase protein expression and nitric oxide production in beta-amyloid stimulated PC12 neurons through p38 MAP kinase and NF-kappaB involvement

1 reference

12 December 2020

Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice.

1 reference

12 December 2020

Marijuana components stimulate human peripheral blood mononuclear cell secretion of interferon-gamma and suppress interleukin-1 alpha in vitro

1 reference

12 December 2020

Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma

1 reference

12 December 2020

Endocannabinoids and beta-amyloid-induced neurotoxicity in vivo: effect of pharmacological elevation of endocannabinoid levels.

1 reference

12 December 2020

Cannabidiol-induced apoptosis in human leukemia cells: A novel role of cannabidiol in the regulation of p22phox and Nox4 expression.

1 reference

12 December 2020

Neutralizing antibodies to interferon-beta may persist after cessation of therapy: what impact could they have?

1 reference

12 December 2020

CB1 receptor selective activation inhibits beta-amyloid-induced iNOS protein expression in C6 cells and subsequently blunts tau protein hyperphosphorylation in co-cultured neurons.

1 reference

12 December 2020

Forebrain-specific inactivation of Gq/G11 family G proteins results in age-dependent epilepsy and impaired endocannabinoid formation

1 reference

12 December 2020

The brain as a target of inflammation: common pathways link inflammatory and neurodegenerative diseases

1 reference

12 December 2020

The endocannabinoid system as an emerging target of pharmacotherapy

1 reference

12 December 2020

R-(+)-[2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)-pyrrolo-[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphtalenylmethanone (WIN-2) ameliorates experimental autoimmune encephalomyelitis and induces encephalitogenic T cell apoptosis: Partial involvement of the

1 reference

12 December 2020

Mechanisms of Disease: astrocytes in neurodegenerative disease

1 reference

12 December 2020

The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset

1 reference

12 December 2020

Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro

1 reference

12 December 2020

Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain

1 reference

12 December 2020

Autologous haematopoietic stem cell transplantation fails to stop demyelination and neurodegeneration in multiple sclerosis.

1 reference

12 December 2020

The endocannabinoid system in targeting inflammatory neurodegenerative diseases

1 reference

12 December 2020

Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells

1 reference

12 December 2020

Interactions of cannabidiol with endocannabinoid signalling in hippocampal tissue.

1 reference

12 December 2020

Delayed treatment with cannabidiol has a cerebroprotective action via a cannabinoid receptor-independent myeloperoxidase-inhibiting mechanism

1 reference

12 December 2020

Opposing control of cannabinoid receptor stimulation on amyloid-beta-induced reactive gliosis: in vitro and in vivo evidence.

1 reference

12 December 2020

Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression

1 reference

12 December 2020

Cannabinoid CB1 receptor stimulation affords neuroprotection in MPTP-induced neurotoxicity by attenuating S100B up-regulation in vitro

1 reference

12 December 2020

Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors.

1 reference

12 December 2020

Cannabis, pain, and sleep: lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine

1 reference

12 December 2020

Nonpsychoactive cannabidiol prevents prion accumulation and protects neurons against prion toxicity.

1 reference

12 December 2020

Novel cannabinoid receptors

1 reference

12 December 2020

Cannabidiol potentiates pharmacological effects of Delta(9)-tetrahydrocannabinol via CB(1) receptor-dependent mechanism

1 reference

12 December 2020

Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial

1 reference

12 December 2020

Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis

1 reference

12 December 2020

Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications

1 reference

12 December 2020

1 reference

12 December 2020

The brain as a target for inflammatory processes and neuroprotective strategies

1 reference

12 December 2020

Neurodegeneration and inflammation

1 reference

12 December 2020

Cannabinoids and neuroprotection in motor-related disorders

1 reference

12 December 2020

Metabolism of cannabidiol by the rat

1 reference

12 December 2020

Protein misfolding and neurodegeneration

1 reference

12 December 2020

Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS.

1 reference

12 December 2020

Effect of cannabidiol on sepsis-induced motility disturbances in mice: involvement of CB receptors and fatty acid amide hydrolase

1 reference

12 December 2020

Controlled clinical trial of cannabidiol in Huntington's disease

1 reference

12 December 2020

Targeting the endocannabinoid system: to enhance or reduce?

1 reference

12 December 2020

Multiple sclerosis: an immune or neurodegenerative disorder?

1 reference

12 December 2020

Neuroinflammation and synaptic plasticity: theoretical basis for a novel, immune-centred, therapeutic approach to neurological disorders.

1 reference

12 December 2020

Microsomal metabolism of the 1",1"-dimethylheptyl analogue of cannabidiol: relative percentage of monohydroxy metabolites in four species

1 reference

12 December 2020

Pharmacokinetics of urinary metabolites of cannabidiol in the dog

1 reference

12 December 2020

Identification of glucose conjugates as major urinary metabolites of cannabidiol in the dog.

1 reference

12 December 2020

Metabolites of cannabidiol identified in human urine

1 reference

12 December 2020

Effect of cannabinoids on spasticity and ataxia in multiple sclerosis

1 reference

12 December 2020

Analgesic and antiinflammatory activity of constituents of Cannabis sativa L

1 reference

12 December 2020

Open label evaluation of cannabidiol in dystonic movement disorders

1 reference

12 December 2020

Cannabidiol interferes with the effects of Δ9-tetrahydrocannabinol in man

1 reference

12 December 2020

Acute and subacute inhalation toxicity of Turkish marihuana, cannabichromene, and cannabidiol in rats

1 reference

12 December 2020

1 reference

12 December 2020

Chemical basis of hashish activity

1 reference

12 December 2020

Toxicity of short-term administration of cannabinoids to rhesus monkeys

1 reference

12 December 2020

Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects

1 reference

12 December 2020

The perceived effects of smoked cannabis on patients with multiple sclerosis

1 reference

12 December 2020

Comparative receptor binding analyses of cannabinoid agonists and antagonists.

1 reference

12 December 2020

Evaluation of cannabinoid receptor agonists and antagonists using the guanosine-5'-O-(3-[35S]thio)-triphosphate binding assay in rat cerebellar membranes.

1 reference

12 December 2020

Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants

1 reference

12 December 2020

Delta9 tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cells

1 reference

12 December 2020

10.1111/J.1755-5949.2008.00065.X

Identifiers

DOI

1 reference

1 July 2019

release_5wqvacmuxfaq5amyjiezmeckza

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/5wqvacmuxfaq5amyjiezmeckza

24 November 2022

mapped directly with Wikidata item

PMC publication ID

6494021

1 reference

1 July 2019

PubMed publication ID

19228180

1 reference

1 July 2019